Mometasonfuroat Teva (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to glucocorticoid receptors in nasal mucosal cells. This binding alters gene transcription, decreasing production of inflammatory mediators like cytokines, prostaglandins, and leukotrienes, while increasing anti‑inflammatory proteins, resulting in reduced nasal inflammation.

The exact dosing regimen is determined by the prescribing healthcare professional based on the patient’s condition and response. Typically, a single spray per nostril once daily is common, but the prescriber may adjust frequency or amount as needed.

Safety data for mometasone furoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasonfuroat Teva contains mometasone furoate, which is generally considered to have high topical potency and low systemic absorption compared with some alternatives such as fluticasone propionate. Both classes reduce nasal inflammation, but individual response, dosing convenience, and specific safety profiles may influence the choice of therapy.

The nasal spray should be stored below 25 °C, in its original container, protected from moisture and direct sunlight. Do not freeze the product. Keep the device upright and avoid exposing it to extreme temperatures to maintain spray performance.

Mometasonfuroat Teva is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The process is repeated in the other nostril if prescribed.

Serious but rare risks include nasal septum perforation, secondary infections of the nasal mucosa, and systemic effects such as adrenal suppression when used at high doses for prolonged periods. Patients should report persistent nosebleeds, severe irritation, or signs of infection promptly.

Mometasonfuroat Teva should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation excipients, those with active untreated nasal infections (especially fungal), and patients who have recently undergone nasal surgery unless directed by a physician.